Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adamgammadex vs Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block
CTR20211477Phase 3Completed
- Sponsor
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adamgammadex in neuromuscular block (NMB), sponsored by Zhejiang Xianju Pharmaceutical Co., Ltd.. Started Jun 2021; status: completed.
02
Drugs
adamgammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on CTR20211477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211477.